News 23.08.2022 Schlieren (Zurich), Switzerland, August 23, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs bone graft has successfully achieved three key clinical and commercial milestones, with completion of enrolment in the PARTNER clinical trial, the first patient treated...
News 23.08.2022 Zurich-Schlieren, Switzerland, August 23, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced the publication of new results comparing its own product Proclarix® and the Prostate Health Index (phi) test from Beckman Coulter. Early detection of prostate cancer is widely performed using screening of total prostate‐specific antigen (PSA)...
News 12.07.2022 Schlieren, Zurich, 12 July 2022 – Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the expansion of its leadership team with the appointment of Samantha Vieira as Chief Operating Officer (COO) and Nate Massari as Chief Business...
News 05.07.2022 Zurich-Schlieren, Switzerland, July 05, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, is pleased to announce that the United States Patent and Trademark Office granted to the company U.S. Patent No. 11,320,435, titled “Method of detecting proteins in human samples and uses of such methods” that...
News 29.06.2022 Zurich-Schlieren, Switzerland, June 29, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases. Study results will be presented...